Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.

Journal Article (Journal Article;Multicenter Study)

Although novel agents (NAs) have improved outcomes for patients with chronic lymphocytic leukemia (CLL), a subset will progress through all available NAs. Understanding outcomes for potentially curative modalities including allogeneic hematopoietic stem cell transplantation (alloHCT) following NA therapy is critical while devising treatment sequences aimed at long-term disease control. In this multicenter, retrospective cohort study, we examined 65 patients with CLL who underwent alloHCT following exposure to ≥1 NA, including baseline disease and transplant characteristics, treatment preceding alloHCT, transplant outcomes, treatment following alloHCT, and survival outcomes. Univariable and multivariable analyses evaluated associations between pre-alloHCT factors and progression-free survival (PFS). Twenty-four-month PFS, overall survival (OS), nonrelapse mortality, and relapse incidence were 63%, 81%, 13%, and 27% among patients transplanted for CLL. Day +100 cumulative incidence of grade III-IV acute graft-vs-host disease (GVHD) was 24%; moderate-severe GVHD developed in 27%. Poor-risk disease characteristics, prior NA exposure, complete vs partial remission, and transplant characteristics were not independently associated with PFS. Hematopoietic cell transplantation-specific comorbidity index independently predicts PFS. PFS and OS were not impacted by having received NAs vs both NAs and chemoimmunotherapy, 1 vs ≥2 NAs, or ibrutinib vs venetoclax as the line of therapy immediately pre-alloHCT. AlloHCT remains a viable long-term disease control strategy that overcomes adverse CLL characteristics. Prior NAs do not appear to impact the safety of alloHCT, and survival outcomes are similar regardless of number of NAs received, prior chemoimmunotherapy exposure, or NA immediately preceding alloHCT. Decisions about proceeding to alloHCT should consider comorbidities and anticipated response to remaining therapeutic options.

Full Text

Duke Authors

Cited Authors

  • Roeker, LE; Dreger, P; Brown, JR; Lahoud, OB; Eyre, TA; Brander, DM; Skarbnik, A; Coombs, CC; Kim, HT; Davids, M; Manchini, ST; George, G; Shah, N; Voorhees, TJ; Orchard, KH; Walter, HS; Arumainathan, AK; Sitlinger, A; Park, JH; Geyer, MB; Zelenetz, AD; Sauter, CS; Giralt, SA; Perales, M-A; Mato, AR

Published Date

  • August 25, 2020

Published In

  • Blood Adv

Volume / Issue

  • 4 / 16

Start / End Page

  • 3977 - 3989

PubMed ID

  • 32841336

Pubmed Central ID

  • PMC7448605

Electronic International Standard Serial Number (EISSN)

  • 2473-9537

Digital Object Identifier (DOI)

  • 10.1182/bloodadvances.2020001956


  • eng

Conference Location

  • United States